Namisaki Tadashi 浪崎正

… Alternative Names

NAMISAKI TADASHI 浪崎正

NAMISAKI Tadashi 浪崎正

Less

Researcher Number	20526850
Other IDs
Affiliation (Current)	2025: 奈良県立医科大学, 医学部, 特任准教授
Affiliation (based on the past Project Information) *help	2025: 奈良県立医科大学, 医学部, 特任准教授 2021 – 2024: 奈良県立医科大学, 医学部, 講師 2015 – 2019: 奈良県立医科大学, 医学部, 講師 2013: 奈良県立医科大学, 医学科, 助教
Review Section/Research Field	Principal Investigator Basic Section 53010:Gastroenterology-related / Medical pharmacy Except Principal Investigator Basic Section 53010:Gastroenterology-related / Gastroenterology
Keywords	Principal Investigator サルコペニア / ウルソデオキシコール酸 / farnesoid X receptor / FXR / OCT1 / 肝癌 / 肝線維化 / 胆汁酸 Except Principal Investigator 肝線維化 / エンドトキシン … More / バイオマーカー / VWF / ADAMTS13 / ARB / NASH / 急性肝不全 / 非アルコール性脂肪肝炎 / 肝癌 / 肝硬変 / 急性腎障害 / ACLF / 肝臓学 / Gut-Liver axis / 肝星細胞 / Leaky Gut / ヒアルロン酸ミセル / 腸肝相関 / equal / 腸内細菌 / equol / エクオール / 血管新生 / DPPⅣ阻害剤 / DPPIV阻害剤 / PAI-1 / DPP4阻害剤 / PAI-1阻害剤 / SGLT-2阻害剤 / DPP-Ⅳ阻害剤 / 生活習慣病 / TNF-α / ウルソデオキシコール酸 / 難吸収性抗菌薬 / 腸管相関 / Toll-like受容体 / 自然免疫 Less

血液凝固制御因子ADAMTS13による肝癌再発予防法とバイオマーカーの開発
- Principal Investigator
  
  高谷広章
- Project Period (FY)
  2025 – 2027
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
A new strategy for the treatment of cirrhotic sarcopenia using a combination of exercise therapy and ADAMTS13 replacement therapy.Principal Investigator
- Principal Investigator
  
  浪崎正
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
Development of Simultaneous Control Therapy for Complications of Cirrhosis Using Enhanced Drug Repositioning
- Principal Investigator
  
  吉治仁志
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
血液凝固制御因子ADAMTS13による急性肝不全新規治療法とバイオマーカーの開発
- Principal Investigator
  
  高谷広章
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
Novel Liver Cirrhosis Treatment by Drug Repositioning and Leaky Gut Control
- Principal Investigator
  
  Yoshiji Hitoshi
- Project Period (FY)
  2021 – 2023
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53010:Gastroenterology-related
- Research Institution
  Nara Medical University
Therapeutic effect of Equol on gut microbiome - mediated NASH progression
- Principal Investigator
  
  NOGUCHI RYUICHI
- Project Period (FY)
  2017 – 2019
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Gastroenterology
- Research Institution
  Nara Medical University
Identification of novel treatment and biomarkers based on pharmacokinetics in patients with hepatocellular carcinomaPrincipal Investigator
- Principal Investigator
  
  Namisaki Tadashi
- Project Period (FY)
  2015 – 2017
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Nara Medical University
Establishment of new treatment targeting lifestyle diseases and coagulation fibrinolytic system related to the development of NASH
- Principal Investigator
  
  Noguchi Ryuichi
- Project Period (FY)
  2014 – 2016
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Gastroenterology
- Research Institution
  Nara Medical University
Gut-liver axis mediated by endotoxin and innate immunity
- Principal Investigator
  
  FUKUI HIROSHI
- Project Period (FY)
  2011 – 2013
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Gastroenterology
- Research Institution
  Nara Medical University

All 2024 2023 2022 2021 2018 2017 2016 2015 2013

All Journal Article Presentation Patent

[Journal Article] Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats2024
- Author(s)
  Asada Shohei、Kaji Kosuke、Nishimura Norihisa、Koizumi Aritoshi、Matsuda Takuya、Tanaka Misako、Yorioka Nobuyuki、Sato Shinya、Kitagawa Koh、Namisaki Tadashi、Akahane Takemi、Yoshiji Hitoshi
- Journal Title
  
  Cells
  
  Volume: 13 Issue: 6 Pages: 538-538
- DOI
  10.3390/cells13060538
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis2024
- Author(s)
  Tanaka Misako、Kaji Kosuke、Nishimura Norihisa、Asada Shohei、Koizumi Aritoshi、Matsuda Takuya、Yorioka Nobuyuki、Tsuji Yuki、Fujinaga Yukihisa、Sato Shinya、Namisaki Tadashi、Akahane Takemi、Yoshiji Hitoshi
- Journal Title
  
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  
  Volume: 1871 Issue: 2 Pages: 119649-119649
- DOI
  10.1016/j.bbamcr.2023.119649
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis2024
- Author(s)
  Asada Shohei、Namisaki Tadashi、Kaji Kosuke、Takaya Hiroaki、et al
- Journal Title
  
  Digestive Diseases and Sciences
  
  Volume: 69 Issue: 3 Pages: 851-869
- DOI
  10.1007/s10620-023-08257-w
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22K08084
[Journal Article] The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure2023
- Author(s)
  Takaya Hiroaki、Namisaki Tadashi、Enomoto Masahide、Kubo Takahiro、Tsuji Yuki、Fujinaga Yukihisa、Nishimura Norihisa、Kaji Kosuke、Kawaratani Hideto、Moriya Kei、Akahane Takemi、Matsumoto Masanori、Yoshiji Hitoshi
- Journal Title
  
  Biology
  
  Volume: 12 Issue: 2 Pages: 164-164
- DOI
  10.3390/biology12020164
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K08084
[Journal Article] A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation2023
- Author(s)
  Suzuki Junya、Kaji Kosuke、Nishimura Norihisa、Kubo Takahiro、Tomooka Fumimasa、Shibamoto Akihiko、Iwai Satoshi、Tsuji Yuki、Fujinaga Yukihisa、Kitagawa Koh、Namisaki Tadashi、Akahane Takemi、Yoshiji Hitoshi
- Journal Title
  
  Biomedicines
  
  Volume: 11 Issue: 5 Pages: 1295-1295
- DOI
  10.3390/biomedicines11051295
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib.2022
- Author(s)
  Fujimoto Y, Namisaki T, Takeda S, Murata K, Enomoto M, Takaya H, Tsuji Y, Fujinaga Y, Sawada Y, Nishimura N, Kitagawa K, Kaji K, Inoue T, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H.
- Journal Title
  
  Anticancer Res
  
  Volume: 42 Issue: 10 Pages: 4895-4905
- DOI
  10.21873/anticanres.15995
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.2022
- Author(s)
  Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H
- Journal Title
  
  Indian J Gastroenterol.
  
  Volume: 41 Issue: 2 Pages: 169-180
- DOI
  10.1007/s12664-021-01220-5
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.2022
- Author(s)
  Enomoto M, Kaji K, Nishimura N, Fujimoto Y, Murata K, Takeda S, Tsuji Y, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Akahane T, Yoshiji H.
- Journal Title
  
  Dig Liver Dis
  
  Volume: 54 Issue: 10 Pages: 1392-1402
- DOI
  10.1016/j.dld.2022.04.012
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Rifaximin enhances the L carnitine mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut liver muscle axis.2022
- Author(s)
  Murata K, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Takeda S, Tsuji Y, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Akahane T, Yoshiji H
- Journal Title
  
  Int J Mol Med.
  
  Volume: 50 Issue: 2 Pages: 101-101
- DOI
  10.3892/ijmm.2022.5157
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity2021
- Author(s)
  Fujimoto Y, Kaji K, Nishimura N, Enomoto M, Murata K, Takeda S, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H.
- Journal Title
  
  World J Gastroenterol.
  
  Volume: 28 Issue: 48 Pages: 8323-8342
- DOI
  10.3748/wjg.v27.i48.8323
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Sulforaphane ameliorates ethanol plus carbon tetrachloride-induced liver fibrosis in mice through the Nrf2-mediated antioxidant response and acetaldehyde metabolization with inhibition of the LPS/TLR4 signaling pathway2021
- Author(s)
  Ishida K, Kaji K, Sato S, Ogawa H, Takagi H, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H
- Journal Title
  
  J Nutr Biochem
  
  Volume: 89 Pages: 108573-108573
- DOI
  10.1016/j.jnutbio.2020.108573
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats2021
- Author(s)
  Takeda S, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Murata K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji　H
- Journal Title
  
  Mol Nutr Food Res
  
  Volume: 65 Issue: 24
- DOI
  10.1002/mnfr.202100526
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K08013
[Journal Article] Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients.2017
- Author(s)
  Namisaki T, Moriya K, Kitade M, Kawaratani H, Takeda K, Okura Y, Takaya H, Nishimura N, Seki K, Kaji K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Nakanishi K, Furukawa M, Saikawa S, Kubo T, Yoshiji H.
- Journal Title
  
  Eur J Gastroenterol Hepatol.
  
  Volume: 29 Pages: 23-30
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K08077
[Journal Article] Effect of combined farnesoid X receptor agonist and angiotensin Ⅱtipe 1 receptor blocker on hepatic fibrosis.2017
- Author(s)
  Namisaki T. Moriya K, Kitade M, Takeda K, Kaji K, Okura Y, Shimozato N. Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya H Yoshiji
- Journal Title
  
  Hepatol commun.
  
  Volume: 1 Issue: 9 Pages: 928945-928945
- DOI
  10.1002/hep4.1104
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K09438, KAKENHI-PROJECT-15K08077
[Journal Article] Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.2016
- Author(s)
  Okura Y,Yoshiji H.
- Journal Title
  
  Hepatol Res
  
  Volume: Dec28 Issue: 12 Pages: 1317-1328
- DOI
  10.1111/hepr.12860
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26461017, KAKENHI-PROJECT-26461018, KAKENHI-PROJECT-15K08077
[Journal Article] Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.2016
- Author(s)
  Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H.
- Journal Title
  
  J Gastroenterol.
  
  Volume: 51 Pages: 162-172
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26461018
[Journal Article] Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.2016
- Author(s)
  Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H
- Journal Title
  
  Ｊｏｕｎａｌ　ｏｆ　Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ
  
  Volume: ５１ Issue: 2 Pages: 162-72
- DOI
  10.1007/s00535-015-1104-x
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K08077, KAKENHI-PROJECT-26461017
[Journal Article] DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis.2016
- Author(s)
  Asada K, Aihara Y, Takaya H, Noguchi R, Namisaki T, Moriya K, Uejima M, Kitade M, Mashitani T, Takeda K, Kawaratani H, Okura Y, Kaji K, Douhara A, Sawada Y, Nishimura N, Seki K, Mitoro A, Yamao J, Yoshiji H.
- Journal Title
  
  World J Hepatol.
  
  Volume: 8 Issue: 28 Pages: 1194-1194
- DOI
  10.4254/wjh.v8.i28.1194
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26461018
[Journal Article] Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.2016
- Author(s)
  Nishimura N, Kitade M, Noguchi R, Namisaki T, Moriya K, Takeda K, Okura Y, Aihara Y, Douhara A, Kawaratani H, Asada K, Yoshiji H.
- Journal Title
  
  J Gastroenterol.
  
  Volume: 未定
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26461018
[Journal Article] Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes.2016
- Author(s)
  Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H, Nakatani T, Kikuchi E, Moriyasu H, Matsumoto M, Sato S, An T, Morita H, Aizawa S, Tokuoka Y, Ishikawa M, Matsumura Y, Ohira H, Kogure A, Noguchi K, Yoshiji H.
- Journal Title
  
  Biomed Rep.
  
  Volume: 4 Pages: 183-187
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26461018
[Journal Article] Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.2015
- Author(s)
  Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K, Okura Y, Kawaratani H, Fukui H.
- Journal Title
  
  Mol Med Rep.
  
  Volume: 11 Pages: 1693-1700
- NAID
  40020982272
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26461018
[Journal Article] Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis2013
- Author(s)
  Shirai Y, Yoshiji H, Noguchi R, Kaji K, Aihara Y, Douhara A, Moriya K, Namisaki T, Kawaratani H, Fukui H.
- Journal Title
  
  J Gastroenterol Hepatol
  
  Volume: 28 Pages: 723-30
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590987
[Journal Article] The effect of inflammatory cytokines in alcoholic liver disease2013
- Author(s)
  Kawaratani H, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T, Noguchi R, Yoshiji H, Fujimoto M, Fukui H.
- Journal Title
  
  Mediators Inflamm.
  
  Volume: 2013 Pages: 495156-495156
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590987
[Journal Article] The effect of inflammatory cytokines in alcoholic liver disease. Mediators2013
- Author(s)
  Kawaratani, H. Tsujimoto, T. Douhara, A. Takaya, H. Moriya, K. Namisaki, T. Noguchi, R. Yoshiji, H. Fujimoto, M. Fukui, H.
- Journal Title
  
  Mediators Inflamm
  
  Volume: 2013 Pages: 495156-495156
- DOI
  10.1155/2013/495156
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590987
[Patent] FXRアゴニストとARBの組み合わせ医薬2017
- Inventor(s)
  浪崎正
- Industrial Property Rights Holder
  浪崎正
- Industrial Property Rights Type
  特許
- Filing Date
  2017
- Overseas
- Data Source
  KAKENHI-PROJECT-15K08077
[Patent] [台湾出願] 1061101802017
- Inventor(s)
  浪崎正、吉治仁志
- Industrial Property Rights Holder
  大日本住友製薬株式会社
- Industrial Property Rights Type
  特許
- Filing Date
  2017-03-27
- Overseas
- Data Source
  KAKENHI-PROJECT-15K08077
[Patent] [PCT出願]　PCT/JP2017/0124482017
- Inventor(s)
  浪崎正、吉治仁志
- Industrial Property Rights Holder
  大日本住友製薬株式会社
- Industrial Property Rights Type
  特許
- Filing Date
  2017-03-27
- Overseas
- Data Source
  KAKENHI-PROJECT-15K08077
[Patent] FXRアゴニストとARBの組み合わせ医薬2017
- Inventor(s)
  浪崎正
- Industrial Property Rights Holder
  浪崎正
- Industrial Property Rights Type
  特許
- Filing Date
  2017
- Overseas
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] Dual Angiotensin II Receptor and Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation2023
- Author(s)
  Suzuki J, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A, Iwai S, Tsuji Y, Fujinaga Y, Kitagawa K, Namisaki T, Akahane T, Yoshiji H
- Organizer
  APASL
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] Glucagon-like Peptide-1 Receptor Agonist, Semaglutide Attenuates Chronic Liver Disease-induced Skeletal Muscle Atrophy in Diabetic Mice2023
- Author(s)
  Iwai S, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A, Suzuki J, Tsuji Y, Fujinaga Y, Kitagawa K, Namisaki T, Akahane T, Yoshiji H
- Organizer
  APASL
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] Rifaximin/L-carnitine 併用による肝硬変ラット骨格筋委縮に対する予防効果2022
- Author(s)
  村田晃児、鍛治孝祐、高谷広章、瓦谷英人、守屋圭、浪崎正、赤羽たけみ、美登路昭、吉治仁志
- Organizer
  日本消化器病学会総会
- Data Source
  KAKENHI-PROJECT-21K08013
[Presentation] ACLFにおけるADAMTS13の動態2022
- Author(s)
  高谷広章, 浪崎正, 鍛治孝祐, 西村典久, 吉治仁志
- Organizer
  第48回日本急性肝不全研究会
- Data Source
  KAKENHI-PROJECT-22K08084
[Presentation] Are the Globe and UK-PBC scrore also effective for predicting risk in patients treated with bezafibrate in addition to ursodeoxycholic acid?:A validation study in Japan2018
- Author(s)
  Tanaka A, Komori A, Abe M, Inao M, Namisaki T, Hashimoto N, Kawata K, Takahashi A, Ninomiya M, Honda A, Hong-Hon K, Arakawa M, Yamagiwa S, Joshita S, Sato K, Kaneko A, Kikuchi K, Itakura J, Nomura T, Kakisaka K, Yoshji H, and et al.
- Organizer
  EASL
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] Biochemical response to ursodeoxycholic acid predicts histologic primary biliary cholangitis progression2018
- Author(s)
  Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Kaji K, Okura Y, Seki K, Takaya H, Sawada Y, Akahane T, Nishimura N, Sato S, Shimozato N, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] Effect of nalfurafine hydrochloride for refractory pruritus in patients with primary biliary cholangitis: a multicenter, postmarketing single-arm, prospective study2018
- Author(s)
  Yagi M, Tanaka A, Namisaki T, Abe M, Takahashi A, Honda A, Matsuzaki Y, Ohira H, Yoshiji H, Takikawa H
- Organizer
  EASL
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] Biochemical response to ursodeoxycholic acid predicts histologic primary ciliary cholangitis progression2018
- Author(s)
  Namisaki T, Fujinaga Y, Moriya K, Kitade M, Kaji K, Kawaratani H, Seki K, Takaya H, Sato S, Sawada Y, Akahane T, Yoshji H
- Organizer
  EASL
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis2017
- Author(s)
  Honda A, Tanak A, Komori A, Abe M, Inao M, Moshida S, Namisaki T, Yoshiji H, Hashimoto N, Kawata K, Takahashi A, Ohira H, and et al.
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] Beneficial effects of combined farnesoid X receptor agonist(INT747) and dipeptidyl peptidase-4 inhibitor(sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis2017
- Author(s)
  Shimozato N, Namisaki T, Moriya K, Kitade M, Takeda K, Kawaratani H, Kaji K, Okura Y, Takaya H, Sawada Y, Nishimura N, Sato S, Saikawa S, Seki K, Furukawa M, Nakanishi K, Kubo T, Yoshiji H
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] Pruritus, dryness, fatigue and health-related quality of life in Japanese patients with primaty biliaty cholangitis2017
- Author(s)
  Yagi M, Tanaka A, Abe M, Namisaki T, Yoshiji H, Takahashi A, Ohira H, Komori A, Yamagiwa S, and et al.
- Organizer
  AASLD
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] DPP4阻害薬及びアンギオテンシンII受容体拮抗薬併用による肝病態進展抑制効2016
- Author(s)
  大倉康志、浪崎正、野口隆一、守屋圭、北出光輝、竹田幸祐、瓦谷英人、相原洋祐、西村典久、佐藤慎哉、澤田保彦、関建一郎、増谷剛、鍛冶孝佑、吉治仁志
- Organizer
  第102回日本消化器病学会総会
- Place of Presentation
  京王プラザホテル
- Year and Date
  2016-04-22
- Data Source
  KAKENHI-PROJECT-26461018
[Presentation] Combination treatment of dipeptidyl peptidase IV inhibitor and angiotensin-II type 1 receptor blocker attenuates progression of nonalcoholic steatohepatitis in rats2016
- Author(s)
  Shinya Sato, Tadashi Namisaki, Kosuke Kaji, Norihisa Nishimura, Yasushi Okura, Ryuichi Noguchi, Kosuke Takeda, Kei Moriya, Mitsuteru Kitade, Kenichiro Seki, Hiroaki Takaya, Hideto Kawaratani, Yasuhiko Sawada, Naotaka Shimozato, Keisuke Nakanishi, Hitoshi Yoshiji
- Organizer
  アメリカ肝臓学会
- Place of Presentation
  ボストン　US
- Year and Date
  2016-11-11
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] Antifibrotic effects of combined treatment with Farnesoid X receptor agonist and angiotensin-II type1 receptor blocker on hepatic fibrogenesis in the rat model of nonalcoholic steatohepatitis2016
- Author(s)
  Tadashi Namisaki, Yasushi Okura, Shinya Sato, Ryuichi Noguchi, Kei Moriya, Mitsuteru Kitade, Kosuke Takeda, Yosuke Aihara, Norihisa Nishimura, Yasuhiko Sawada, Kenichiro Seki, Hideto Kawaratani, Kosuke Kaji, Hitoshi Yoshiji.
- Organizer
  ヨーロッパ肝臓学会
- Place of Presentation
  バルセロナ　スペイン
- Year and Date
  2016-04-13
- Data Source
  KAKENHI-PROJECT-15K08077
[Presentation] 内因性エンドトキシン制御による肝線維化抑制：作用機序の検討2013
- Author(s)
  堂原彰敏、堂原彰敏, 吉治仁志, 守屋圭, 野口隆一, 浪崎正, 相原洋祐, 瓦谷英人, 福井博
- Organizer
  第49回日本肝臓学会総会
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-23590987
[Presentation] 内因性エンドトキシン制御による肝線維化抑制作用機序の検討2013
- Author(s)
  堂原彰敏,吉治仁志,守屋圭,野口隆一,浪崎正,相原洋祐,瓦谷英人,福井博
- Organizer
  第49回日本肝臓学会総会
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-23590987
[Presentation] ウルソデオキシコール酸とアンジオテンシンII受容体阻害薬併用によるNASH線維化進展抑制の試み2013
- Author(s)
  浪崎　正、吉治仁志、福井　博
- Organizer
  第49回日本肝臓学会総会（ワークショップ５）
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-23590987
[Presentation] Beneficial effects of combined treatment with ursodoxycholic acid (UDCA) and Angiotensin-IItype1 receptor blocker(ARB) on liver fibrosis development in the rat model of nonalcoholic steatohepatitis2013
- Author(s)
  Namisaki T, Yoshiji H, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Kawaratani H, Nishimura N, Fukui H.
- Organizer
  Annual Meeting of the Japanese Society for the Research of Hepatic Cells
- Place of Presentation
  大阪
- Year and Date
  2013-09-26
- Data Source
  KAKENHI-PROJECT-23590987
[Presentation] NASH肝線維化進展における腸管透過性亢進の役割2013
- Author(s)
  堂原彰敏,吉治仁志,守屋圭,野口隆一,浪崎正,相原洋祐,瓦谷英人,北出光輝,福井博
- Organizer
  第17回日本肝臓学会大会
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-23590987
[Presentation] Inhibition of endotoxin cascade with antibiotics attenuates the liver fibrosis development in rat model of nonalcoholic steatohepatitis2013
- Author(s)
  Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Aihara Y, Kawaratani H, Nishimura N, Fukui H.
- Organizer
  International Society for Hepatic Sinusoidal Research
- Place of Presentation
  大阪
- Year and Date
  2013-09-24
- Data Source
  KAKENHI-PROJECT-23590987
[Presentation] ウルソデオキシコール酸とアンジオテンシンII受容体阻害薬併用によるNASH肝線維化進展抑制の試み2013
- Author(s)
  浪崎正,吉治仁志,福井博
- Organizer
  第49回日本肝臓学会総会
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-23590987

1. YOSHIJI Hitoshi (40336855)

# of Collaborated Projects: 9 results

# of Collaborated Products: 42 results
2. 鍛治孝祐 (20623490)

# of Collaborated Projects: 5 results

# of Collaborated Products: 17 results
3. Noguchi Ryuichi (30423908)

# of Collaborated Projects: 3 results

# of Collaborated Products: 9 results
4. 高谷広章 (40745460)

# of Collaborated Projects: 3 results

# of Collaborated Products: 3 results
5. KITADE MITSUTERU (40526795)

# of Collaborated Projects: 2 results

# of Collaborated Products: 13 results
6. Moriya Kei (40526852)

# of Collaborated Projects: 2 results

# of Collaborated Products: 13 results
7. Nishimura Norihisa

# of Collaborated Projects: 2 results

# of Collaborated Products: 11 results
8. FUKUI HIROSHI (80145838)

# of Collaborated Projects: 1 results

# of Collaborated Products: 10 results
9. FUJIMOTO Masao (60295805)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
10. MATSUMOTO MASANORI (60316081)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
11. MASHITANI TSUYOSHI (20401929)

# of Collaborated Projects: 1 results

# of Collaborated Products: 3 results
12. 井上隆 (00783044)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
13. 芝本彰彦 (20896724)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
14. 佐藤慎哉 (80790352)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results

Namisaki Tadashi 浪崎 正

NAMISAKI TADASHI 浪崎 正

NAMISAKI Tadashi 浪崎 正

Research Projects

Research Products

Co-Researchers

血液凝固制御因子ADAMTS13による肝癌再発予防法とバイオマーカーの開発

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

A new strategy for the treatment of cirrhotic sarcopenia using a combination of exercise therapy and ADAMTS13 replacement therapy.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of Simultaneous Control Therapy for Complications of Cirrhosis Using Enhanced Drug Repositioning

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

血液凝固制御因子ADAMTS13による急性肝不全新規治療法とバイオマーカーの開発

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Novel Liver Cirrhosis Treatment by Drug Repositioning and Leaky Gut Control

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Therapeutic effect of Equol on gut microbiome - mediated NASH progression

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Identification of novel treatment and biomarkers based on pharmacokinetics in patients with hepatocellular carcinomaPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Establishment of new treatment targeting lifestyle diseases and coagulation fibrinolytic system related to the development of NASH

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Gut-liver axis mediated by endotoxin and innate immunity

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure2023

Author(s)

Journal Title

DOI

Data Source

Namisaki Tadashi 浪崎正

NAMISAKI TADASHI 浪崎正

NAMISAKI Tadashi 浪崎正